RxDoctor Payments Data

Eric Brock, MD

Orthopaedic Surgery · Mineral Wells, TXNPI 1396938973

Payments from drug & device makers

$420in general payments, 2019–2025

Across 11 payments — averaging $38.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$107
  • Bioventus LLC$96
  • Pacira Cryotech Incorporated$95
  • Johnson & Johnson$57
  • Integra Lifesciences Corporation$48
  • Smith+Nephew$17

What the payments were for

  • Food & beverage$420100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Zimmer Biomet1$107
Bioventus LLC5$96
Pacira Cryotech Incorporated1$95
Johnson & Johnson2$57
Integra Lifesciences Corporation1$48
Smith+Nephew1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$420 in reported general payments places this provider in the 15th percentile of 1,337 orthopaedic surgery providers in Texas.

See all orthopaedic surgery providers in Texas

Medicare billing

Part B allowed, 2024
$151,556
Medicare patients
216
Services billed
1,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban28$11,613
Celecoxib259$5,414
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen181$1,842
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen55$704
Tizanidine Hcl115$609
Meloxicam177$435
Gabapentin32$321
Ibuprofen42$287
Promethazine Hcl38$228
Acetaminophen-CodeineAcetaminophen With Codeine16$223
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim30$183
Clindamycin Hcl13$159
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$135
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$132
Naproxen15$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$57$11,61328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,337 orthopaedic surgery providers in Texas.

Other orthopaedic surgery in Mineral Wells

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →